Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase NA 1Phase 1/2 1

Status

Withdrawn 3Completed 3Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Tumor With Alterations of the FGF-R 1Lung Neoplasms 1Breast Neoplasms 1Acrocephalosyndactylia 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × infigratinib × Clear all
NCT01928459 2020-12-09

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Novartis

Phase 1 Completed
62 enrolled
Breast

Acrocephalosyndactylia, Breast Neoplasms

NCT01697605 2020-12-08

A Phase I Study of Oral BGJ398 in Asian Patients

Novartis

Phase 1 Completed
9 enrolled

Tumor With Alterations of the FGF-R

NCT01004224 2019-10-04

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Novartis

Phase 1 Completed
208 enrolled
GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡